Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer
01 Abril 2019 - 08:00AM
Surface Oncology (NASDAQ:SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, today announced the
appointment of Wendy Dwyer as chief business officer. Ms. Dwyer
will be responsible for Surface’s business development, program and
alliance management, and portfolio strategy functions.
“We are excited to welcome Wendy to Surface. Her
deal-making expertise and broad-ranging industry experience bring
tremendous value to our team,” said Jeff Goater, chief executive
officer. “Business development is a key component of our overall
strategy, with partnerships and collaborations of all types playing
an important role as we look to maintain a leadership position in
the rapidly evolving immuno-oncology competitive landscape.”
Ms. Dwyer brings more than twenty years of
business development leadership and deep industry and transactional
experience to her role at Surface. Prior to joining Surface, Ms.
Dwyer most recently served as the chief business officer at
privately-held Portal Instruments, where she led the origination,
negotiation and execution of partnership agreements. Prior to
Portal, she held business development leadership roles across
multiple therapeutic areas with a key focus in oncology at both
AstraZeneca and Ipsen Biosciences. Previously, she held
business development roles of increasing responsibility at Endo and
Indevus Pharmaceuticals.
“Surface’s broad pipeline, deep scientific
expertise and outstanding culture make it an exciting team to join
at a time when immuno-oncology research is presenting so many new
therapeutic opportunities with life-changing potential for patients
suffering with cancer,” said Ms. Dwyer. “Surface’s compelling
programs are pushing the frontiers of immunobiology and I look
forward to fostering high-caliber partnerships that will further
enable Surface’s strategic vision.”
About Surface Oncology:Surface
Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment with lead programs targeting CD73, CD39, IL-27 and
CD47. Surface’s novel cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. The
company has a pipeline of seven novel immunotherapies and a
strategic collaboration with Novartis focused on NZV930
(CD73) and potentially one additional undisclosed program.
For more information, please
visit www.surfaceoncology.com.
Contacts: InvestorsSeth Lewis
slewis@surfaceoncology.com 617-665-5031
Media:Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
Surface Oncology (NASDAQ:SURF)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Surface Oncology (NASDAQ:SURF)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024